Protara TARA-002 STARBORN-1: 100% clinical success in evaluable patients

Protara Therapeutics, Inc.

8/8 evaluable patients (100%) achieved clinical success at eight-week assessment.
80% (8/10) of patients that completed treatment achieved clinical success.
5/6 macrocystic patients had complete response; mixed cystic patient also complete response.
No serious adverse events; common AEs were swelling and fatigue; one discontinuation due to Grade 2 fatigue.
Two LMs patients reached 32-week post-treatment and remain disease-free.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.